SI2744826T1 - Kombinirana terapija s protitelesom proti CD19 in analogom purina - Google Patents
Kombinirana terapija s protitelesom proti CD19 in analogom purinaInfo
- Publication number
- SI2744826T1 SI2744826T1 SI201231992T SI201231992T SI2744826T1 SI 2744826 T1 SI2744826 T1 SI 2744826T1 SI 201231992 T SI201231992 T SI 201231992T SI 201231992 T SI201231992 T SI 201231992T SI 2744826 T1 SI2744826 T1 SI 2744826T1
- Authority
- SI
- Slovenia
- Prior art keywords
- antibody
- combination therapy
- purine analog
- purine
- analog
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161523862P | 2011-08-16 | 2011-08-16 | |
| EP11177660 | 2011-08-16 | ||
| PCT/EP2012/065904 WO2013024095A1 (en) | 2011-08-16 | 2012-08-14 | Combination therapy with an anti - cd19 antibody and a purine analog |
| EP12745883.4A EP2744826B1 (en) | 2011-08-16 | 2012-08-14 | Combination therapy with an anti-cd19 antibody and a purine analog |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2744826T1 true SI2744826T1 (sl) | 2022-05-31 |
Family
ID=47714800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201231992T SI2744826T1 (sl) | 2011-08-16 | 2012-08-14 | Kombinirana terapija s protitelesom proti CD19 in analogom purina |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US20140227277A1 (OSRAM) |
| EP (2) | EP2744826B1 (OSRAM) |
| JP (1) | JP6114273B2 (OSRAM) |
| KR (3) | KR102117202B1 (OSRAM) |
| CN (1) | CN103703027B (OSRAM) |
| AU (1) | AU2012296905B2 (OSRAM) |
| BR (1) | BR112013033916B1 (OSRAM) |
| CA (1) | CA2841738C (OSRAM) |
| CY (1) | CY1125148T1 (OSRAM) |
| DK (1) | DK2744826T3 (OSRAM) |
| ES (1) | ES2909720T3 (OSRAM) |
| HR (1) | HRP20220224T1 (OSRAM) |
| HU (1) | HUE058855T2 (OSRAM) |
| IL (1) | IL230295B (OSRAM) |
| LT (1) | LT2744826T (OSRAM) |
| MX (1) | MX353589B (OSRAM) |
| PL (1) | PL2744826T3 (OSRAM) |
| PT (1) | PT2744826T (OSRAM) |
| RS (1) | RS63121B1 (OSRAM) |
| RU (1) | RU2664462C9 (OSRAM) |
| SG (1) | SG10201606788VA (OSRAM) |
| SI (1) | SI2744826T1 (OSRAM) |
| SM (1) | SMT202200160T1 (OSRAM) |
| WO (1) | WO2013024095A1 (OSRAM) |
| ZA (1) | ZA201401835B (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2514591A (en) * | 2013-05-30 | 2014-12-03 | Mologen Ag | Predictive biomarker for cancer therapy |
| ES2523901B1 (es) * | 2013-05-31 | 2015-12-02 | Universidad Autónoma de Madrid | Uso de la deguelina como terapia suplementaria de la leucemia linfoide crónica |
| IL249533A0 (en) * | 2014-06-16 | 2017-02-28 | Xencor Inc | Treatment of chronic lymphocytic leukemia |
| US20170137516A1 (en) * | 2014-06-16 | 2017-05-18 | Xencor, Inc. | Treatment for chronic lymphocytic leukemia (cll) |
| US10617691B2 (en) * | 2015-05-26 | 2020-04-14 | Morphosys Ag | Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereof |
| DK3337506T3 (da) | 2015-08-21 | 2021-09-06 | Morphosys Ag | Kombinationer og anvendelser deraf |
| SMT202100291T1 (it) * | 2016-05-30 | 2021-07-12 | Morphosys Ag | Metodi per prevedere il beneficio terapeutico di una terapia anti-cd19 in pazienti |
| SG10202104036QA (en) * | 2016-10-28 | 2021-05-28 | Morphosys Ag | Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof |
| CA3062400A1 (en) | 2017-05-31 | 2018-12-06 | Morphosys Ag | Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment |
| CN110945028B (zh) | 2017-07-10 | 2023-09-08 | 国际药物发展生物技术公司 | 用非岩藻糖基化促凋亡抗cd19抗体与抗cd20抗体或化疗剂联合治疗b细胞恶性肿瘤 |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| WO2020150513A1 (en) * | 2019-01-17 | 2020-07-23 | Fred Hutchinson Cancer Research Center | Methods to enhance the selectivity and effectiveness of cancer treatments |
| TW202334231A (zh) * | 2021-12-22 | 2023-09-01 | 德商莫菲西斯公司 | 抗cd19抗體療法的治療範例 |
| WO2025012080A1 (en) | 2023-07-13 | 2025-01-16 | Christian-Albrechts-Universität Zu Kiel | Humanized anti-cd7 antibody |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11852A (en) | 1854-10-31 | Abraham bassford | ||
| US106A (en) | 1915-08-24 | Specipication | ||
| US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
| JP2002522511A (ja) * | 1998-08-11 | 2002-07-23 | アイデック ファーマスーティカルズ コーポレイション | 抗ｃｄ２０抗体の投与を含むｂ細胞リンパ腫の併用療法 |
| WO2000074718A1 (en) | 1999-06-09 | 2000-12-14 | Immunomedics, Inc. | Immunotherapy of autoimmune disorders using antibodies which target b-cells |
| CN1592645A (zh) | 2000-09-18 | 2005-03-09 | 拜奥根Idec公司 | 使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法 |
| US7771951B2 (en) | 2001-12-03 | 2010-08-10 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
| US20080260731A1 (en) * | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
| EP1648512A4 (en) | 2003-07-31 | 2009-01-21 | Immunomedics Inc | ANTI-CD19 ANTIBODIES |
| US7902338B2 (en) * | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| US8444973B2 (en) | 2005-02-15 | 2013-05-21 | Duke University | Anti-CD19 antibodies and uses in B cell disorders |
| JP5215180B2 (ja) | 2005-06-20 | 2013-06-19 | メダレックス インコーポレーティッド | Ｃｄ１９抗体およびその使用法 |
| US20070136826A1 (en) * | 2005-12-02 | 2007-06-14 | Biogen Idec Inc. | Anti-mouse CD20 antibodies and uses thereof |
| ES2365046T3 (es) * | 2005-12-30 | 2011-09-21 | Merck Patent Gmbh | Anticuerpos anti-cd19 con inmunogenicidad reducida. |
| ME01786B (me) * | 2006-08-14 | 2014-09-20 | Xencor Inc | Optimizovana antitela usmerena na cd19 |
| CN103694349A (zh) | 2006-09-08 | 2014-04-02 | 米迪缪尼有限公司 | 人源化抗cd19抗体及其在治疗癌症、移植病和自身免疫病中的应用 |
| EP3392273A1 (en) | 2007-05-30 | 2018-10-24 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| CN101903403B (zh) | 2007-10-19 | 2016-03-16 | 西雅图基因公司 | Cd19结合剂及其应用 |
| WO2010095031A2 (en) | 2009-02-23 | 2010-08-26 | Glenmark Pharmaceuticals S.A. | Humanized antibodies that bind to cd19 and their uses |
| CA2765080C (en) | 2009-06-24 | 2018-07-17 | The Feinstein Institute For Medical Research | Methods for treating chronic lymphocytic leukemia |
| TWI409079B (zh) * | 2009-08-14 | 2013-09-21 | Roche Glycart Ag | 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法 |
| AR077867A1 (es) * | 2009-08-14 | 2011-09-28 | Roche Glycart Ag | Terapia combinatoria de un anticuerpo cd20 afucosilado con fludarabina y/o mitoxantrona |
| WO2011057222A1 (en) * | 2009-11-06 | 2011-05-12 | Infinity Pharmaceuticals, Inc. | Oral formulations of a hedgehog pathway inhibitor |
-
2012
- 2012-08-14 HU HUE12745883A patent/HUE058855T2/hu unknown
- 2012-08-14 BR BR112013033916-0A patent/BR112013033916B1/pt active IP Right Grant
- 2012-08-14 DK DK12745883.4T patent/DK2744826T3/da active
- 2012-08-14 EP EP12745883.4A patent/EP2744826B1/en active Active
- 2012-08-14 SM SM20220160T patent/SMT202200160T1/it unknown
- 2012-08-14 ES ES12745883T patent/ES2909720T3/es active Active
- 2012-08-14 RS RS20220314A patent/RS63121B1/sr unknown
- 2012-08-14 CN CN201280036572.4A patent/CN103703027B/zh active Active
- 2012-08-14 KR KR1020197022418A patent/KR102117202B1/ko active Active
- 2012-08-14 KR KR1020207014644A patent/KR20200060779A/ko not_active Withdrawn
- 2012-08-14 HR HRP20220224TT patent/HRP20220224T1/hr unknown
- 2012-08-14 SI SI201231992T patent/SI2744826T1/sl unknown
- 2012-08-14 PL PL12745883T patent/PL2744826T3/pl unknown
- 2012-08-14 SG SG10201606788VA patent/SG10201606788VA/en unknown
- 2012-08-14 JP JP2014525432A patent/JP6114273B2/ja active Active
- 2012-08-14 PT PT127458834T patent/PT2744826T/pt unknown
- 2012-08-14 EP EP22155604.6A patent/EP4083071A3/en active Pending
- 2012-08-14 LT LTEPPCT/EP2012/065904T patent/LT2744826T/lt unknown
- 2012-08-14 MX MX2013014935A patent/MX353589B/es active IP Right Grant
- 2012-08-14 KR KR1020147006942A patent/KR20140071368A/ko not_active Ceased
- 2012-08-14 WO PCT/EP2012/065904 patent/WO2013024095A1/en not_active Ceased
- 2012-08-14 AU AU2012296905A patent/AU2012296905B2/en active Active
- 2012-08-14 CA CA2841738A patent/CA2841738C/en active Active
- 2012-08-14 RU RU2014103490A patent/RU2664462C9/ru active
- 2012-08-14 US US14/127,217 patent/US20140227277A1/en not_active Abandoned
-
2014
- 2014-01-02 IL IL230295A patent/IL230295B/en active IP Right Grant
- 2014-03-12 ZA ZA2014/01835A patent/ZA201401835B/en unknown
-
2020
- 2020-04-03 US US16/839,903 patent/US20200352975A1/en not_active Abandoned
-
2022
- 2022-04-14 CY CY20221100284T patent/CY1125148T1/el unknown
-
2024
- 2024-02-20 US US18/581,959 patent/US20240424012A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201401835B (en) | Combination therapy with an anti-cd19 antibody and a purine analog | |
| IL281250A (en) | Anti-PHF-tau antibodies and uses thereof | |
| DK2729170T3 (en) | Antibody variants and uses thereof | |
| IL232407A0 (en) | Tests and methods for choosing treatment methods for those with depression | |
| EP2756094A4 (en) | ANTI-B7-H4 ANTIBODIES AND USES THEREOF | |
| EP2712427A4 (en) | SEISMIC DETECTION WITH TWO-COMPONENT SOURCE AND DEGHOSTING OF SOURCE | |
| GB201110783D0 (en) | Methods and uses | |
| IL230293B (en) | Combined treatment with anti-19cd antibody and nitrogen mustard | |
| GB201116774D0 (en) | Uses and methods | |
| IL224953A (en) | Theobromine-containing preparations and their use in combination with a debilitating drug | |
| EP2716359A4 (en) | COMPLEX AND USES THEREOF | |
| EP2721788A4 (en) | METHOD AND ARRANGEMENT FOR SENDING QUESTIONS | |
| GB201108490D0 (en) | Methods and uses | |
| AU340918S (en) | A vehicle and a toy vehicle | |
| ZA201401628B (en) | Antiballistic article with resin | |
| GB201114341D0 (en) | Reagent and use | |
| GB201119443D0 (en) | GoWinging Concept and patent | |
| IL215565A0 (en) | Bed with accessible and usable space | |
| GB201107656D0 (en) | Short back and sides |